Resources
-
Sub-visible Particle Characterization
Roundtable 4 Notes: Higher Order Structure 2021
-
Analytical Ultracentrifugation
Roundtable 3 Notes: Higher Order Structure 2021
-
Best Practice for Analyzing and Interpreting Routine Biophysical Assays (DLS, CD, DSC)
Roundtable 2 Notes: Higher Order Structure 2021
-
Ervebo® vaccine for Ebola virus – a case study on approaches to accelerate process development and tech transfer
Speaker Presentation Califano Joseph, Merck & Co. Inc., 2021
-
COVID Vaccines: Expediting Development While Ensuring Product Quality
Speaker Presentation Levis Robin, CBER, FDA, 2021
-
CMC Considerations From Development Through Registration of An Autologous CAR-T Therapy
Speaker Presentation Gillet Delphine, Novartis Pharma AG, 2021
-
Vector-based ATMP Development in the EU Regulatory and Scientific Considerations
Speaker Presentation Reischl Ilona, AGES MEA, 2021
-
Regulatory Considerations for CAR T Cell Development
Speaker Presentation Schultz Kimberly, CBER, FDA, 2021
-
Product and Process Characterization – The Data Sources for an Adequate Control Strategy
Speaker Presentation Gross Steffen, Paul-Ehrlich-Institut, 2021
-
Justification of Specification & Life-cycle Management of Relevant Analytical Methods
Speaker Presentation Backofen Ulli, Boehringer Ingelheim, 2021
-
Analytical Similarity Assessment for Biosimilar Initial Approval, Lifecycle Management, and Extrapolation of Indications
Speaker Presentation Liu Jennifer, Amgen Inc., 2021
-
Comparability Exercise for Biologics: A Case Study
Speaker Presentation Chang Andrew, Novo Nordisk Inc., 2021
-
Risk-based Comparability for Biological Products (Perspectives from a multi-national company)
Speaker Presentation Edwards Julia, Genentech, a Member of the Roche Group, 2021
-
Application and Review: Trends in the Past Decade of Chinese Biopharmaceuticals
Speaker Presentation Wei Kaikun, Center for Drug Evaluation (CFDA), 2021
-
The Criticality of Efficient CMC Changes Through the Product Lifecycle
Speaker Presentation Montgomery Frank, AstraZeneca, 2021
-
Update of Q12 Implementation in Japan - China
Speaker Presentation Yagi Satomi, Kyowa Hakko Kirin Co. Ltd., 2021
-
CMC Regulatory Expectations for Biological Therapeutic Products for Life Cycle Management and EUA Applications, a CDER/FDA Perspective
Speaker Presentation Jing Xianghong (Emily), CDER, FDA, 2021
-
Strategies to Establish Release Specifications for Peptide Maps
CMC Summary Paper: CMC Strategy Forum North America Fall 2002
-
Analysis and Structure Characterization of Monoclonal Antibodies
CMC Summary Paper: CMC Strategy Forum North America Winter 2003
-
What Is Test Method Qualification?
CMC Summary Paper: CMC Strategy Forum North America Summer 2003